Industry experts say biotechs must prioritize validation, maturity, and alternative financing to overcome a lack of long-term funding.
Funding lifelines: How to cross the 'valley of death'
Related Posts
Global air cargo volumes rise 5% in November, but e-commerce momentum cools
The final stretch of 2025 had been expected to deliver only modest activity, yet volumes in September and October surprised on the upside with 3% […]
Unicorn-Entrepreneurship Is The Opposite Of Venture Capital
Over the last decade, the word unicorn has become synonymous with venture capital: billion-dollar valuations, massive funding rounds, and founders who often lose control long […]
776 Founding Partner Katelin Holloway Shares How to Decide Whether Venture Capital Is Right for Your Business
Raising venture capital can be a game changer or a mistake. Katelin Holloway of 776 shares when VC makes sense and when it doesn’t.